- 專利名稱(中文) / 利用人類疾病實驗動物模式開發保健食品之研究
- 專利名稱(英文) / Human diseased animal models for the development of pharmaceuticals and functional foods
- 所屬單位(一級單位) / 獸醫學院
- 所屬單位(二級單位) / 獸醫學系
- 發明人(中文) / 陳文英
- 發明人(英文) / Wen-Ying Chen
- 申請國家 /
- 專利類型 /
- 專利證書號 / Mao FC, Chen WY. Composition for preventing and treating fatty liver. Number: US8,711,752B2.
- 技術成熟度 /
利用人類疾病之實驗動物模式研究開發機能性保健食品之功效與改善效果。目前已建立之疾病動物模式包括腦中風、糖尿病、肝硬化、非酒精性脂肪肝、動脈粥樣硬化、肥胖、癌症研究。
Research interest Development of health foods and new treatment strategies based on human diseased animal models. Current established human diseased animal models Including stroke, diabetes, hepatic cirrhosis, nonalcoholic fatty liver, atherosclerosis, obesity and tumor animal models. Publish Papers: Chen WY, Mao FC, Liu CH, Kuan YH, Lia NW, Wu CC, Chen CJ. Chromium supplementation improved post-stroke brain infarction and hyperglycemia. Metabolic Brain Disease 2016, 31:289-297. Chen TY, Wang MMC, Hsieh SK, Hsieh MH, Chen WY*, Tzen JTC. Pancreatic lipase inhibition of strictinin isolated from Pu’er tea (Cammelia sinensis) and its anti-obesity effects in C57BL6 mice. Journal of Functional Foods 2018, 48: 1-8. (*equal to corresponding author) Yang CP, Wang YY, Lin SY, Hong YJ, Liao KY, Hsieh SK, Pan PH, Chen CJ, Chen WY. Olanzapine induced dysmetabolic changes involving tissue chromium mobilization in female rats. Int J Mol Sci 2019, 20(3): E640. Patent: Mao FC, Chen WY. Composition for preventing and treating fatty liver. Number: US8,711,752B2.
Animal model (實驗動物模式)
